OBJECTIVE: To look for genetic mutations that might predict central compartment lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) using strict criteria for N0 and N1 disease. DESIGN: We identified patients with PTC from our institution's pathology archives. Strict criteria were used for assessing the presence or the absence of central neck LNM. Disease was classified as N0 only if a comprehensive ipsilateral and pretracheal central neck dissection was performed and if pathological analysis revealed no evidence of LNM. Primary tumor samples were analyzed for a panel of known or suspected PTC-associated molecular markers, including BRAF, RET -PTC, KRAS, NRAS, HRAS, PIK3CA, and their variants. SETTING: Academic medical center. PATIENTS: Three hundred eighty-nine patients with PTC. MAIN OUTCOME MEASURE: Molecular mutations in tumors with and without LNM. RESULTS: Of 389 identified cases, 209 fit the inclusion criteria, with 158 classified as node positive (N1) and 51 as node negative (N0). The follicular variant histological type was present in 7 of 158 N1 tumors (4.4%) and 24 of 51 N0 tumors (47.1%) and thus was strongly associated with lack of central neck metastasis in this study (odds ratio, 0.05; 95% CI, 0.02-0.14). Predictive factors for central LNM included extracapsular extension, angiolymphatic invasion, and higher T stage (T3 and T4). The BRAF mutation was more prevalent in the classic PTC histological type than the follicular variant. None of the molecular marker mutations that were analyzed in this study, including the BRAF mutation, predicted LNM in classic PTC. CONCLUSIONS: Positive risk factors for central LNM include male sex, extracapsular extension, angiolymphatic invasion, and advanced T stage. The follicular variant histological type has a significantly lower incidence of central neck metastasis. In contrast to recent studies, the BRAF mutation was not significantly associated with central neck LNM from PTC when using a strict definition of a central neck dissection.
OBJECTIVE: To look for genetic mutations that might predict central compartment lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) using strict criteria for N0 and N1 disease. DESIGN: We identified patients with PTC from our institution's pathology archives. Strict criteria were used for assessing the presence or the absence of central neck LNM. Disease was classified as N0 only if a comprehensive ipsilateral and pretracheal central neck dissection was performed and if pathological analysis revealed no evidence of LNM. Primary tumor samples were analyzed for a panel of known or suspected PTC-associated molecular markers, including BRAF, RET -PTC, KRAS, NRAS, HRAS, PIK3CA, and their variants. SETTING: Academic medical center. PATIENTS: Three hundred eighty-nine patients with PTC. MAIN OUTCOME MEASURE: Molecular mutations in tumors with and without LNM. RESULTS: Of 389 identified cases, 209 fit the inclusion criteria, with 158 classified as node positive (N1) and 51 as node negative (N0). The follicular variant histological type was present in 7 of 158 N1 tumors (4.4%) and 24 of 51 N0 tumors (47.1%) and thus was strongly associated with lack of central neck metastasis in this study (odds ratio, 0.05; 95% CI, 0.02-0.14). Predictive factors for central LNM included extracapsular extension, angiolymphatic invasion, and higher T stage (T3 and T4). The BRAF mutation was more prevalent in the classic PTC histological type than the follicular variant. None of the molecular marker mutations that were analyzed in this study, including the BRAF mutation, predicted LNM in classic PTC. CONCLUSIONS: Positive risk factors for central LNM include male sex, extracapsular extension, angiolymphatic invasion, and advanced T stage. The follicular variant histological type has a significantly lower incidence of central neck metastasis. In contrast to recent studies, the BRAF mutation was not significantly associated with central neck LNM from PTC when using a strict definition of a central neck dissection.
Authors: Brian Hung-Hin Lang; Cathy Po-Ching Ng; Kin Bun Au; Kai Pun Wong; Kandy K C Wong; Koon Yat Wan Journal: World J Surg Date: 2014-10 Impact factor: 3.352
Authors: Kathleen C Lee; Carol Li; Eric B Schneider; Yongchun Wang; Helina Somervell; Matthew Krafft; Christopher B Umbricht; Martha A Zeiger Journal: Surgery Date: 2012-10-11 Impact factor: 3.982
Authors: Bálint Tobiás; Csaba Halászlaki; Bernadett Balla; János P Kósa; Kristóf Árvai; Péter Horváth; István Takács; Zsolt Nagy; Evelin Horváth; János Horányi; Balázs Járay; Eszter Székely; Tamás Székely; Gabriella Győri; Zsuzsanna Putz; Magdolna Dank; Zsuzsanna Valkusz; Béla Vasas; Béla Iványi; Péter Lakatos Journal: Pathol Oncol Res Date: 2015-08-11 Impact factor: 3.201
Authors: B Balla; B Tobiás; J P Kósa; J Podani; P Horváth; Z Nagy; J Horányi; B Járay; E Székely; L Krenács; K Árvai; M Dank; Z Putz; B Szabó; B Szili; Z Valkusz; B Vasas; G Győri; P Lakatos; I Takács Journal: J Endocrinol Invest Date: 2014-09-09 Impact factor: 4.256
Authors: Danuta Gąsior-Perczak; Artur Kowalik; Agnieszka Walczyk; Monika Siołek; Krzysztof Gruszczyński; Iwona Pałyga; Estera Mikina; Tomasz Trybek; Janusz Kopczyński; Ryszard Mężyk; Stanisław Góźdź; Aldona Kowalska Journal: Cancers (Basel) Date: 2019-11-07 Impact factor: 6.639
Authors: Ana Carolina de Jesus Paniza; Thais Biude Mendes; Matheus Duarte Borges Viana; Débora Mota Dias Thomaz; Paula B O Chiappini; Gabriel A Colozza-Gama; Susan Chow Lindsey; Marcos Brasilino de Carvalho; Venâncio Avancini Ferreira Alves; Otavio Curioni; André Uchimura Bastos; Janete Maria Cerutti Journal: Endocr Connect Date: 2019-11 Impact factor: 3.335